AIRLINK 159.45 Increased By ▲ 4.49 (2.9%)
BOP 10.06 Increased By ▲ 0.15 (1.51%)
CNERGY 7.85 Increased By ▲ 0.48 (6.51%)
CPHL 83.56 Increased By ▲ 0.65 (0.78%)
FCCL 48.54 Increased By ▲ 0.68 (1.42%)
FFL 15.07 Increased By ▲ 0.39 (2.66%)
FLYNG 49.46 Increased By ▲ 4.50 (10.01%)
HUBC 141.41 Increased By ▲ 3.44 (2.49%)
HUMNL 12.74 Decreased By ▼ -0.13 (-1.01%)
KEL 4.45 Increased By ▲ 0.16 (3.73%)
KOSM 5.34 Increased By ▲ 0.18 (3.49%)
MLCF 76.36 Increased By ▲ 1.05 (1.39%)
OGDC 213.73 Increased By ▲ 1.06 (0.5%)
PACE 5.33 Increased By ▲ 0.18 (3.5%)
PAEL 46.96 Increased By ▲ 0.83 (1.8%)
PIAHCLA 17.24 Increased By ▲ 0.96 (5.9%)
PIBTL 8.85 Increased By ▲ 0.28 (3.27%)
POWER 15.09 Decreased By ▼ -0.09 (-0.59%)
PPL 173.25 Increased By ▲ 3.34 (1.97%)
PRL 33.82 Increased By ▲ 2.68 (8.61%)
PTC 22.06 Increased By ▲ 2.01 (10.02%)
SEARL 84.13 Increased By ▲ 0.36 (0.43%)
SSGC 36.98 Increased By ▲ 0.91 (2.52%)
SYM 15.51 Increased By ▲ 0.61 (4.09%)
TELE 7.56 Increased By ▲ 0.35 (4.85%)
TPLP 8.56 Increased By ▲ 0.14 (1.66%)
TRG 65.19 Decreased By ▼ -1.01 (-1.53%)
WAVESAPP 9.25 Increased By ▲ 0.30 (3.35%)
WTL 1.28 Increased By ▲ 0.03 (2.4%)
YOUW 3.68 Increased By ▲ 0.08 (2.22%)
BR100 12,888 Increased By 217.2 (1.71%)
BR30 38,116 Increased By 748.7 (2%)
KSE100 119,962 Increased By 1425.4 (1.2%)
KSE30 36,773 Increased By 479.3 (1.32%)

NEW YORK: A Hawaii court ordered Bristol-Myers Squibb and Sanofi to pay the state $834 million over marketing claims for blood thinner, Plavix, according to news reports.

The two pharmaceutical giants said they intend to appeal the decision, which concluded that the companies engaged in unfair and deceptive business practices.

The state of Hawaii alleged the companies misled consumers about the benefit of using the drug, particularly for people of East Asian ancestry.

The drug makers “intend to appeal the trial court’s decision and we are confident in our success on appeal,” the companies said.

The state pointed to results showing the treatment did not work well for some patients of Asian or Pacific-island descent who could not properly metabolize the drug, according to the reports.

But the two companies disagreed, saying, “Leading cardiologists have examined the scientific evidence and continue to recommend Plavix as the standard of care for all its indications regardless of race or ethnicity.

Comments

Comments are closed.

OSZAR »